Recent Updates in The Role of Immunotherapies in Early NSCLC: Translating Evidence to Clinical Practice - Episode 12

Treatment for Patients Unsuitable for or Refractory to Consolidation Durvalumab

, , ,

Tina Cascone, MD, Ben Levy, MD, and Sandip Patel, MD, offer insights into the treatment approach in patients with unresectable early-stage NSCLC who are unsuitable for consolidation durvalumab or who progress on consolidation durvalumab.

EP. 1: Overview of Early-Stage NSCLC and Molecular Testing
EP. 2: Selecting Optimal Treatment in Early-Stage NSCLC
EP. 3: Neoadjuvant Therapy in Early-Stage NSCLC: CheckMate-816 Study
EP. 4: Perioperative Treatment in Early-Stage NSCLC: AEGEAN Study
EP. 5: Perioperative Treatment in Early NSCLC: KEYNOTE-671 and NEOTORCH Studies
EP. 6: Neoadjuvant Versus Perioperative Therapy in Resectable NSCLC
EP. 7: Neoadjuvant Versus Adjuvant Therapy in Resectable NSCLC
EP. 8: Adjuvant Therapy in NSCLC: IMPower-010 and KEYNOTE-091 Studies
EP. 9: Treatment Strategy in Patients with Unresectable Stage I-III NSCLC
EP. 10: Consolidation Immunotherapy in Unresectable Early NSCLC: PACIFIC Study
EP. 11: Consolidation Immunotherapy in Unresectable Early NSCLC: Novel Approaches
Now Viewing
EP. 12: Treatment for Patients Unsuitable for or Refractory to Consolidation Durvalumab
EP. 13: Practice Pearls for Community Oncologists Treating Early-Stage NSCLC

Related Content:

Recent Updates in The Role of Immunotherapies in Early NSCLC: Translating Evidence to Clinical PracticeLung CancerImmunotherapy in Lung Cancer
Dr Owonikoko on the Impact of the FDA Approval of Tarlatamab in ES-SCLC
Dr Ramalingam on Updates in Lung Cancer Following the 2024 ASCO Annual Meeting
FDA Issues CRL for Patritumab Deruxtecan in Pretreated EGFR+ NSCLC